A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The Specific aims of this project are to (1) test the prediction that pain from tampon
insertion (primary outcome measure) is lower in PVD patients when treated with gabapentin
compared to when treated with placebo. Secondary outcome measures include intercourse pain
and 24-hour pain and (2)perform a mechanism-based analysis of gabapentin effectiveness, and
to gain insight into the underlying pathophysiology of subtypes of PVD that may lead to more
specific treatment options.